sudok1 / iStockphoto.com
Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.
Disease complications, antibiotic resistance, and even death. These are just some of the consequences counterfeit drugs can have.
According to the World Health Organization (WHO), up to two billion people cannot get medicines that are crucial to their health, while many millions are at risk of falling into abject poverty due to healthcare costs they cannot afford. The organization says that this limited access to quality medicines “creates a vacuum that is too often filled by substandard and falsified products”.
The WHO estimates that one in ten medical products circulating in low and middle-income countries is either substandard or counterfeit.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
counterfeit, bigpharma, generics, counterfeit medicines, patents, World Health Organization, WHO,Alban Kang, Bird & Bird, Rouse, Gunawan Suryomurcito
